Dianthus Therapeutics
DNTH
63 hedge funds and large institutions have $406M invested in Dianthus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 7 closing their positions.
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
225% more capital invested
Capital invested by funds: $125M → $406M (+$281M)
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
17% more funds holding
Funds holding: 54 → 63 (+9)
0.47% more ownership
Funds ownership: 4.15% → 4.62% (+0.47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$19.7M |
| 2 |
BlackRock
New York
|
+$6.24M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$4.52M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.94M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$3.59M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$1.85M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.1M |
| 4 |
ACA
Anchor Capital Advisors
Boston,
Massachusetts
|
-$1.03M |
| 5 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$849K |
DNTH Hedge Fund Activity: Q1 2019 in Review
63 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2019, worth a combined $406M — up 225% from $125M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new DNTH positions and 7 closed out — a net gain of 9 holders — while 23 added to existing stakes and 7 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $19.7M. The largest seller was Fidelity International, exiting entirely with an estimated $3.59M sold.
- 63 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2019, up from 54 in Q4 2018.
- Funds reported $406M of Dianthus Therapeutics stock for Q1 2019, up 225% quarter-over-quarter.
- 16 funds opened new Dianthus Therapeutics positions in Q1 2019 and 7 closed out, a net change of +9 holders.
- The largest Dianthus Therapeutics buyer in Q1 2019 was Gilder Gagnon Howe & Co, an estimated $19.7M added.
- The largest Dianthus Therapeutics seller in Q1 2019 was Fidelity International, an estimated $3.59M sold.
Based on aggregated 13F filings for Q1 2019.